– Dermaliq Therapeutics, Inc. is an unbiased personal pharmaceutical firm emerged from Novaliq

– Spin-off to unlock worth within the area of medical dermatology through the use of Novaliq’s transformative know-how outdoors eye care

– 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd be a part of as new traders

– Proceeds shall be used for 3 Phase 1/2a scientific growth packages in dermatology

WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ — Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. as we speak introduced the institution of Dermaliq Therapeutics, Inc (Dermaliq), a newly fashioned Delaware-based pharmaceutical growth firm, and the signing of a USD 15 million Series A financing spherical. 3E Bioventures Capital, a number one worldwide life science investor, led the spherical and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq’s current shareholder Novaliq has transferred, and licensed Intellectual Property (IP) associated to the sphere of dermatology to Dermaliq.

Skin ailments are the fourth main reason behind non-fatal illness burden worldwide, underscoring the function of dermatology within the rising area of world well being. Skin situations have vital impression on sufferers’ well-being, psychological well being, and social participation. Although topical and native supply of energetic elements to diseased pores and skin is the popular remedy route for almost all of sufferers, present therapies usually lack passable pores and skin penetration and affected person compliance.

Dermaliq is creating the subsequent technology of skincare therapies to boost focused penetration into pores and skin tissues and to scale back undesirable uncomfortable side effects for thousands and thousands of sufferers. The distinctive and proprietary know-how now owned by Dermaliq, referred to as hyliQ™, is designed to permit cutaneous drug supply with unmatched bioavailability. The know-how allows the event of superior, extremely efficient liquid drug merchandise with distinctive beauty properties.

The proceeds shall be used to conduct three Phase 1/2a scientific dermatology packages with the purpose to show security and efficacy and to advance this novel skincare drug class to market to enhance the lives of thousands and thousands of sufferers:

DLQ01 is a liquid drug candidate for the topical remedy of feminine and male androgenetic alopecia, focusing on the prostamide E2 (PGE2) receptor in hair bulbs by means of particular follicular drug supply.
DLQ02 is a novel and liquid topical calcineurin inhibitor drug remedy for plaque psoriasis, notably in troublesome to deal with areas.
DLQ03 is a broad-spectrum liquid antibiotic drug candidate that targets topical remedy of bacterial pores and skin and comfortable tissue infections, together with the discount of antibiotic-resistant strains.

The Company has demonstrated proof-of-principle for enhanced topical drug supply utilizing hyliQ™ in nonclinical fashions for all three purposes.

“We are excited that 3E Bioventures Capital and Beijing Whale Technology Corporation have dedicated to assist Dermaliq as new traders within the Series A spherical,” stated Dr. Frank Löscher, Chief Executive Officer of Dermaliq. “Our spin-off from Novaliq and profitable elevating of great funds gives us with the chance to construct a number one specialty pharmaceutical firm and broaden the appliance of Novaliq’s transformative drug supply know-how into dermatology.”

“3E is dedicated to investing in international main life sciences and biomedical corporations and assist them develop with entry to globalized sources and capabilities,” stated Karen Liu, Managing Director 3E Bioventures Capital. “Dermaliq is utilizing a novel, and scientifically sound know-how to attain excessive effectivity drug supply throughout the pores and skin. The know-how is already confirmed in ophthalmology and holds nice promise for dermatology. We shall be excited to discover extra drug pipelines in China and synergize with Dermaliq on each pre-clinical and scientific growth.”

“Whale Technology values the strong science basis of Dermaliq’s proprietary hyliQ™ know-how platform,” stated Ming Gao, founder and Chief Executive Officer of Whale Technology Co. Ltd. “Dermaliq’s founding crew demonstrates an incredible mixture of science, scientific expertise and commercialization energy. We see nice potential of Dermaliq’s pipeline within the area of dermatology after Novaliq’s confirmed scientific and business success in ophthalmology.”

“Dermatology is the logical subsequent step into utilizing Novaliq’s proprietary know-how platform outdoors eye care,” stated Dr. Christian Roesky, Chief Executive Officer Novaliq. “The spin-off into an unbiased firm permits Dermaliq to enormously profit from our expertise in ophthalmology whereas being totally dedicated to the a number of product growth actions in dermatology, and more likely to additional broaden its pipeline to different pores and skin situations.”

To replicate the brand new shareholder construction, Karen Liu of 3E Bioventures Capital will be a part of Dermaliq’s Board of Directors. Dr. Löscher has additionally transitioned from his function as Chief Technology Officer at Novaliq to guide Dermaliq as its CEO & President.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a personal firm based in 2021 by means of a spin off from Novaliq to reimagine topical dermatology. The Company is included in Wilmington (DE), USA below Delaware legislation. The firm has signed a USD 15 million collection A spherical to advance three transformative skincare drug therapies by means of scientific trials. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

About 3E Bioventures Capital:

3E Bioventures Capital is a healthcare enterprise capital agency, devoted to investing in cutting-edge life sciences and biomedical applied sciences, with a deal with breakthrough first-in-class therapies and disruptive cross-disciplinary improvements in medical units and diagnostics. 3E Bioventures takes on a science-driven, entrepreneur-friendly funding philosophy by working carefully with corporations and analysis establishments to develop medication or merchandise which have robust unmet medical wants. With places of work in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its expertise, capabilities, and community to assist corporations faucet into markets and sources throughout the Pacific and advance with better velocity and capital effectivity. The motto of 3E Bioventures Capital is captured in its title 3E: Expertise, Efficiency, Execution.

About Beijing Whale Technology Corporation Ltd.:

Beijing Whale Technology Corporation Ltd. is a China-based pharmaceutical group dedicated to the long-term sustainable growth within the fields of chemistry, prescribed drugs and aesthetics. With greater than 20 years of historical past, Whale Tech. has developed two core enterprise items. On one hand, Whale Pharmaceutical Co. Ltd., Whale Chemistry Co. Ltd. and Whale Pharmatech Co. Ltd. are grouped as pharmaceutical and chemistry enterprise unit. On the opposite hand, Whale Biotech is a analysis stage biotech firm with the main focus of creating aesthetics merchandise.

About Novaliq:

Novaliq is a biopharmaceutical firm specializing in the event and commercialization of first- and best-in-class ocular therapeutics based mostly on EyeSol®, the worldwide first water-free eyedrop know-how. Novaliq affords an industry-leading portfolio addressing as we speak’s unmet medical wants of thousands and thousands of sufferers with eye ailments. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an workplace in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an energetic investor in Life and Health Sciences corporations.

Logo – https://mma.prnewswire.com/media/1728174/Dermaliq_Therapeutics_Logo.jpg

For additional info, please contact:
Dermaliq Therapeutics Inc.
Dr. Frank Löscher
Chief Executive Officer 
+49 6221 50259-272

SOURCE Dermaliq Therapeutics


Source link

#Dermaliq #Therapeutics #Signs #USD #Million #Series #Advance #Transformative #Drug #Therapies #Clinical #Trials

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *